[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai 10th People's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":609},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,43,66,88,111,136,165,191,211,232,255,276,299,319,343,367,388,410,432,459,485,506,529,556,586],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100644389","assessment-of-the-effects-and-safety-of-spermidine-supplementation-on-blood-lipids-and-body-weight-in-overweight-or-obese-individuals-with-hyperlipidemia-100644389",false,"NCT07662330","Assessment of the Effects and Safety of Spermidine Supplementation on Blood Lipids and Body Weight in Overweight or Obese Individuals With Hyperlipidemia","Assessment of the Effects and Safety of Spermidine Supplementation on Blood Lipids and Body Weight in Overweight or Obese Individuals With Hyperlipidemia: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Males or females aged 18 to 65 years.\n* BMI ≥ 24 kg\u002Fm², without severe chronic diseases.\n* Not currently using glucose-lowering or lipid-lowering medications.\n* Dyslipidemia defined as triglycerides ≥ 1.7 mmol\u002FL or total cholesterol ≥ 5.2 mmol\u002FL.\n* No active weight loss or weight gain diet within the past 1 month.\n* No special dietary pattern changes (e.g., ketogenic, vegan, high-protein, meal replacement, intermittent fasting) within the past 1 month.\n* No use of supplements that may affect polyamine intake (e.g., germ, yeast, fermented extracts, nutritional powders) within the past 2-4 weeks.\n* Willing and able to provide signed informed consent.\n\nExclusion Criteria:\n\n* Diagnosis of acute or severe gastrointestinal disease\n* Concurrent participation in any other weight-loss therapy\n* Current use of hypoglycemic or lipid-lowering medications\n* Participation in any other clinical trial within one month prior to signing the informed consent form\n* Pregnancy, lactation, or planning a pregnancy during the trial period\n* Known allergy to cellulose or wheat\n* History of cancer\n* Renal insufficiency, indicated by abnormal serum creatinine levels\n* Hepatic impairment, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>3 × upper limit of normal (ULN), or total bilirubin (TBIL) \\>3 × ULN\n* Any other condition deemed by the investigator as inappropriate for trial participation","ALL","18 Years","60 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","Evaluate the effect of spermidine supplementation on lipid profile changes in individuals with overweight or obesity accompanied by hyperlipidemia. Analyze the impact of spermidine on metabolic parameters and assess the safety of spermidine supplementation, including liver and kidney function, gastrointestinal reactions, and other adverse effects.",[28,29],"Obesity & Overweight","Hyperlipidemia","RECRUITING","2026-06-22",{"date":33,"type":34},"2026-06-23","ACTUAL",{"date":36,"type":34},"2026-01-01",{"date":38,"type":22},"2027-01-31",{"name":40,"class":41},"Shanghai 10th People's Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100638350","phase-1-a-multicenter-clinical-study-of-romiplostim-n01-in-the-treatment-of-sepsis-related-thrombocytopenia-100638350","NCT07595133","A Multicenter Clinical Study of Romiplostim N01 in the Treatment of Sepsis-related Thrombocytopenia","ITJ(QN)2510","Inclusion Criteria:\n\n* Age ≥ 18 years old, gender unrestricted.\n* Meeting the diagnostic criteria of sepsis 3.0, namely: a) confirmed or suspected infection; b) organ dysfunction caused by infection, that is, Sequential Organ Failure Assessment (SOFA) score ≥ 2 points. If organ dysfunction is known to exist before infection, that is, the SOFA score is greater than 0 points, then the SOFA score must increase by ≥ 2 points after the infection occurs.\n* Platelet count ≤ 50×109\u002FL.\n* The subjects must fully understand and be able to comply with the requirements of the research protocol, and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Subjects who are allergic to romiplostim N01 or thrombopoietin, or who have previously received romiplostim N01 or thrombopoietin treatment but showed no therapeutic effect.\n* Subjects who have undergone cardiopulmonary resuscitation or have end-stage liver or kidney failure.\n* Subjects with thrombocytopenia caused by hematological diseases, or with other hypercoagulable state diseases, recent thrombosis, or acute active bleeding.\n* Subjects who have participated in other drug clinical studies within one month.\n* Subjects who have used anticoagulants or antiplatelet drugs (such as aspirin, clopidogrel, etc.) within three weeks.\n* Subjects who have received platelet-raising treatment (such as methylprednisolone, platelet transfusion, intravenous immunoglobulin or TPO antirheumatic drugs) within two weeks.\n* Subjects who have received immunomodulatory agent treatment within six months.\n* Subjects who have undergone splenectomy within six months.\n* Subjects with a history of radiotherapy or chemotherapy for malignant tumors or with advanced malignant tumors.\n* Subjects who have previously received allogeneic stem cell transplantation or organ transplantation.\n* Subjects with severe cardiovascular and cerebrovascular diseases, severe trauma, major surgery, or other causes of major bleeding.\n* Subjects who were transferred out or died within 24 hours of admission (or ICU).\n* Subjects with known or suspected immunosuppression history, including invasive opportunistic infection history (such as histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis); or subjects with complex long-term infections.\n* Women who are currently pregnant or breastfeeding, or plan to become pregnant or breastfeed during the study; and men whose partners plan to become pregnant during the study.\n* Subjects whom the investigator deems unsuitable for participation in this study for any other reason.",{"count":51,"type":22},280,[53],"PHASE1","This study intends to randomly divide the SAT patients admitted to the ICU into the ropivacaine N01 treatment group and the recombinant human thrombopoietin control group. By measuring the platelet count of the SAT patients, the therapeutic effect of ropivacaine N01 will be evaluated. Moreover, through the APACHE II score of the patients, the improvement of platelet technology, the 28-day mortality rate, the incidence of adverse reactions, the length of ICU stay and the hospitalization cost, the advantages and social value of ropivacaine N01 in treating SAT will be explored.",[56],"Sepsis","NOT_YET_RECRUITING","2026-05-12",{"date":60,"type":34},"2026-05-19",{"date":62,"type":22},"2026-06-01",{"date":64,"type":22},"2027-12-31",{"name":40,"class":41},{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":76,"conditions":77,"keywords":78,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100637112","evaluating-the-diagnostic-performance-and-impact-on-clinical-outcomes-of-the-nurapid-crispr-pathogen-profile-assay-in-icu-patients-with-sepsis-100637112","NCT07580001","Evaluating the Diagnostic Performance and Impact on Clinical Outcomes of the NuRapid-CRISPR Pathogen Profile Assay in ICU Patients With Sepsis","A Multicenter Prospective Study Evaluating the Diagnostic Performance and Impact on Clinical Outcomes of the NuRapid-CRISPR Pathogen Profile Assay in ICU Patients With Sepsis","Inclusion Criteria:\n\n* Age ≥ 18 years, length of stay in the ICU ≤ 24 hours;\n* Meets the Sepsis-3.0 diagnostic criteria (an increase in SOFA score of ≥2 points from baseline, and evidence of infection);\n* Clinically suspected sepsis or septic shock; the pathogen is unknown; the clinical plan is to collect sterile or suitable specimens, such as blood, respiratory specimens, cerebrospinal fluid, and ascites, for microbiological testing;\n* Expected ICU stay of ≥48 hours and ability to complete at least 28 days of clinical follow-up;\n* A written informed consent form signed by the patient or their legally authorized representative;\n\nExclusion Criteria:\n\n* At the time of admission, the patient had already received a definitive pathogen diagnosis (based on microbiological culture, reliable molecular testing, or serological evidence), and targeted antimicrobial therapy against that pathogen had been initiated for more than 48 hours;\n* Vital signs are extremely unstable; death is expected within 24 hours;\n* Patients with severe primary immunodeficiency (e.g., AIDS, active hematologic malignancies, post-transplantation of solid organs or hematopoietic stem cells, or long-term use of high-dose glucocorticoids \\[prednisone ≥ 20 mg\u002Fday or equivalent dose for more than 4 weeks\\] or other potent immunosuppressants);\n* Women who are pregnant or breastfeeding;\n* The patient or their authorized representative has expressly refused to undergo any pathogen testing;\n* It is not possible to obtain a suitable specimen for testing due to anatomical, physiological, or technical reasons;\n* The patient is currently participating in another interventional clinical trial that may interfere with the assessment of the primary outcome of this study;\n* The patient or their authorized representative has declined to participate in this study;",{"count":74,"type":22},396,[25],"This study is a prospective, multicenter, integrated trial designed to evaluate, from the perspectives of diagnostic performance and clinical utility, whether a diagnostic and treatment strategy based on the NuRapid-CRISPR rapid pathogen detection technology can reduce the 28-day all-cause mortality rate in patients with sepsis or septic shock in the ICU, compared to traditional pathogen culture.\n\nThe study consists of two parts:\n\n1. Diagnostic Accuracy Study: For all enrolled sepsis patients, microbiological specimens will undergo concurrent blinded testing, with NuRapid-CRISPR serving as the test of interest and traditional pathogen culture as the reference standard. A prospective comparison will evaluate differences between the two methods in key metrics such as pathogen detection rate, sensitivity, specificity, and turnaround time.\n2. Clinical Utility Cohort Study: All patients will undergo NuRapid-CRISPR testing as part of routine clinical care. Based on whether the rapid results are adopted clinically to guide early antimicrobial therapy decisions, the cohort will naturally form an exposure group (early treatment adjustments based on NuRapid-CRISPR results) and a control group (treatment primarily based on traditional culture results or empirical therapy). The study will prospectively compare the two groups in terms of the time to optimize antimicrobial therapy, coverage of the initial treatment spectrum, and infection-related clinical outcomes.",[56],[56,79],"Pathogen Detection Technologies","2026-05-06",{"date":58,"type":34},{"date":83,"type":22},"2026-07",{"date":85,"type":22},"2028-12",{"name":40,"class":41},3,{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":42},"100633542","an-observational-multicenter-study-to-evaluate-the-effectiveness-of-guselkumab-for-the-treatment-of-participants-with-crohns-disease-after-surgical-resection-100633542","NCT07528040","An Observational, Multicenter Study to Evaluate the Effectiveness of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection","POST-CD","Inclusion Criteria:\n\n* Patients≥ 18，\n* Have a documented diagnosis of moderate to severe CD\n* Have undergone an ileocolonic surgical resection\n\nExclusion Criteria:\n\n* Has complications of CD, such as short bowel syndrome Currently has or is suspected to have an abscess\n* Active infection\n* Currently has a malignancy or has a history of malignancy within 5 years",{"count":96,"type":22},88,"OBSERVATIONAL","The goal of this single arm ,non-interventional, prospective, descriptive study is to evaluate the efficacy of guselkumab treatment in preventing endoscopic recurrence of Crohn's Disease in adult participants who have a documented diagnosis of moderate to severe CD and have undergone an ileocolonic surgical resection. The primary endpoint is Endoscopic recurrence rate at week24.",[100],"Crohn's Disease (CD)",[102],"IBD","2026-04-07",{"date":105,"type":34},"2026-04-14",{"date":107,"type":22},"2026-04-15",{"date":109,"type":22},"2029-05-31",{"name":40,"class":41},{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100632108","phase-2-fmt-combined-with-standard-first-line-therapy-in-initially-unresectable-colorectal-cancer-100632108","NCT07509398","FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer","Efficacy and Safety of Fecal Microbiota Transplantation Combined With First-Line Standard Therapy in Patients With Initially Unresectable Colorectal Cancer: A Multicenter, Open-Label, Randomized Controlled Trial","Inclusion Criteria:\n\n* (1) Subjects must volunteer to participate in this study, sign the informed consent form (ICF), and demonstrate good compliance.\n\n  (2) Patients aged 18 to 75 years (inclusive). (3) Meet the defined criteria for initially unresectable advanced metastatic colorectal cancer (mCRC) for this project.\n\n  (4) Have not received first-line standard therapy. (5) Prior radiotherapy is permitted, provided it was completed more than 4 weeks prior to enrollment.\n\n  (6) ECOG performance status of 0 to 1. (7) Life expectancy of ≥ 24 weeks. (8) Adequate major organ function meeting the following criteria (without the use of any blood components or cell growth factors within 2 weeks prior to enrollment): (9) Bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL, white blood cell (WBC) count ≥ 4.0 × 10\\^9\u002FL, platelets ≥ 100 × 10\\^9\u002FL, hemoglobin ≥ 90 g\u002FL.\n\n  (10) Hepatic function: Serum total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); if total bilirubin \\> 1.5 × ULN, direct bilirubin must be ≤ ULN. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN (allowed up to 5 × ULN for patients with liver metastases).\n\n  (11) Renal function: Blood urea nitrogen (BUN) and creatinine (Cr) ≤ 1.5 × ULN (and creatinine clearance rate (CCr) ≥ 50 mL\u002Fmin).\n\n  (12) Cardiac function: Normal cardiac function with a left ventricular ejection fraction (LVEF) ≥ 50%.\n\n  (13) Coagulation: International normalized ratio (INR) ≤ 1.5 × ULN, activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.\n\n  (14) Male or female patients of childbearing potential must volunteer to use effective contraceptive methods (e.g., double-barrier methods, condoms, oral or injectable contraceptives, intrauterine devices) during the study and for 6 months after the last dose of study medication. All female patients are considered to be of childbearing potential unless they are naturally postmenopausal, artificially postmenopausal, or surgically sterilized (e.g., hysterectomy, bilateral oophorectomy, or pelvic irradiation). Otherwise, female patients must have a negative serum pregnancy test (within 7 days prior to study enrollment) and must not be lactating.\n\nExclusion Criteria:\n\n* (1) Presence of symptoms such as bleeding, perforation, or obstruction at the primary tumor site.\n\n  (2) Presence of secondary intracranial tumors (brain metastases). (3) History of severe autoimmune diseases: active inflammatory bowel disease (including Crohn's disease, ulcerative colitis), rheumatoid arthritis, scleroderma, systemic lupus erythematosus, autoimmune vasculitis (e.g., Wegener's granulomatosis), etc.\n\n  (4) Symptomatic interstitial lung disease, or active infectious\u002Fnon-infectious pneumonitis.\n\n  (5) Risk factors for intestinal perforation: active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, or other known risk factors for intestinal perforation.\n\n  (6) Patients who have undergone other surgeries must wait for complete wound healing before being considered for enrollment.\n\n  (7) History of other malignancies; except for cured localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, and carcinoma in situ of the prostate, cervix, or breast, which are permitted for enrollment.\n\n  (8) Patients planning to undergo or who have previously undergone organ transplantation or allogeneic bone marrow transplantation.\n\n  (9) Moderate to severe ascites with clinical symptoms requiring therapeutic paracentesis or drainage, or a Child-Pugh score \\> 2 (excluding cases with only a small amount of ascites shown on imaging without clinical symptoms); uncontrolled or moderate to large pleural or pericardial effusions.\n\n  (10) History of gastrointestinal bleeding within 6 months prior to the start of study treatment or a clear tendency for gastrointestinal bleeding, such as esophageal\u002Fgastric varices with bleeding risk or severe varices, localized active gastrointestinal ulcer lesions, or persistently positive fecal occult blood (if fecal occult blood is positive at baseline, it can be retested; if still positive, an esophagogastroduodenoscopy (EGD) is required. If EGD indicates esophageal\u002Fgastric varices with a risk of bleeding, the patient cannot be enrolled).\n\n  (11) Occurrence of an abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to the start of study treatment.\n\n  (12) Patients who presented with signs\u002Fsymptoms of incomplete obstruction\u002Fobstructive syndrome\u002Fileus at initial diagnosis may be enrolled if the symptoms have completely resolved following definitive (surgical) treatment.\n\n  (13) Known hereditary or acquired bleeding disorders (e.g., coagulopathy) or thrombotic tendency, such as hemophilia; current or recent (within 10 days prior to study treatment) use of full-dose oral or injectable anticoagulants or thrombolytic agents for therapeutic purposes (prophylactic use of low-dose aspirin or low molecular weight heparin is allowed).\n\n  (14) Current or recent (within 10 days prior to study treatment) use of aspirin (\\> 325 mg\u002Fday, maximum antiplatelet dose), dipyridamole, ticlopidine, clopidogrel (≥ 75 mg), or cilostazol.\n\n  (15) Occurrence of thrombotic or embolic events within 6 months prior to the start of study treatment, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral infarction), pulmonary embolism, etc.\n\n  (16) Active infection, heart failure, myocardial infarction within 6 months, unstable angina, or unstable arrhythmias.\n\n  (17) Lactating or pregnant women. (18) History of hepatic encephalopathy. (19) Use of immunosuppressants or systemic corticosteroids for immunosuppressive purposes (dose \\> 10 mg\u002Fday of prednisone or equivalent) within 14 days prior to the start of study treatment.\n\n  (20) Known severe allergic reaction to any monoclonal antibodies or anti-angiogenic targeted drugs.\n\n  (21) Any other factors that, in the judgment of the investigator, may affect the study results or lead to premature termination of the study, such as alcohol abuse, drug abuse, other severe diseases (including psychiatric disorders) requiring concomitant treatment, or severe laboratory abnormalities.","75 Years",{"count":120,"type":22},220,[122,123],"PHASE2","PHASE3","This clinical trial evaluates the efficacy and safety of adding fecal microbiota transplantation (FMT) to first-line standard of care for patients with initially unresectable colorectal cancer (CRC).\n\nFMT is an established procedure designed to restore intestinal microbiome homeostasis by transferring processed fecal microbiota from a rigorously screened healthy donor into the patient's gastrointestinal tract. The standard first-line treatment regimen typically consists of chemotherapy, with or without targeted therapy.\n\nApproximately 220 patients across 13 participating centers will be randomly assigned to receive either standard therapy alone or standard therapy combined with FMT. The primary endpoint is the objective response rate (ORR). Secondary endpoints include the conversion to resectability rate, progression-free survival (PFS), safety and adverse events, quality of life (QoL), anxiety and depression scales, as well as dynamic changes in the gut microbiome and circulating biomarkers.\n\nThe ultimate goal of this trial is to determine whether microbiome modulation via FMT can synergistically enhance the antitumor efficacy of standard first-line therapies and mitigate treatment-related toxicities in this patient population.",[126,127],"Unresectable Colorectal Cancer","Colorectal Cancer (Locally Advanced or Metastatic)","2026-03-29",{"date":130,"type":34},"2026-04-03",{"date":132,"type":22},"2026-04",{"date":134,"type":22},"2031-12",{"name":40,"class":41},{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":146,"studyType":97,"phases":4,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":164},"100403070","burden-of-new-onset-atrial-fibrillation-in-patients-with-acute-myocardial-infarction-100403070","NCT04528511","BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction","BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction: the BENEFIT-AMI Multicenter Prospective Registry","BENEFIT-AMI","Inclusion Criteria:\n\n* Adult patients (\\>18 years old);\n* Patient with AMI (including STEMI and NSTEMI) who developed NOAF during the index hospitalization;\n* Patients must have received in-hospital CEM for at least 5 days;\n* Patients must give informed consent.\n\nExclusion Criteria:\n\n* Patients with a medical history of pre-existing AF;\n* Patients with a medical history of rheumatic valvular disease;\n* Patients with a medical history of sick sinus syndrome;\n* Patients undergoing emergent coronary artery bypass surgery;\n* Patients who suffer malignant tumors with an expected lifetime less than 1 year ;\n* Patients who refuse to receive CEM during hospitalization and the data of heart rhythm cannot be retrieved;\n* Patients who refuse to receive percutaneous coronary intervention (PCI) or have contraindications for PCI;\n* Patients who have died during the index hospitalization.",{"count":145,"type":22},774,"2 Years","To validate the prognostic importance of the burden of new-onset atrial fibrillation (NOAF) complicating acute myocardial infarction (AMI) in a prospectively designed hospital-based registry. To characterize those factors that contribute to the progression of post-MI NOAF burden. To establish a prediction model for the risk stratification of patients with NOAF complicating AMI. To explore the clinical usefulness of NOAF burden in guiding the anticoagulation therapy among patients with post-MI NOAF.",[149,150],"Atrial Fibrillation New Onset","Acute Myocardial Infarction",[150,152,153,154,155],"New-Onset Atrial Fibrillation","Burden","Prospective","Cardiovascular Outcomes","2026-03-16",{"date":158,"type":34},"2026-03-19",{"date":160,"type":34},"2020-10-01",{"date":162,"type":22},"2028-06-30",{"name":40,"class":41},5,{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":172,"minAge":18,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":42},"100519747","multidisciplinary-diagnosis-and-treatment-of-polycystic-ovary-syndrome-100519747","NCT06047574","Multidisciplinary Diagnosis and Treatment of Polycystic Ovary Syndrome","Multidisciplinary Combined Precise Diagnosis and Treatment of Polycystic Ovary Syndrome","Inclusion Criteria:\n\n* Female aged 18- 45;\n\nExclusion Criteria:\n\n* Female patients younger than 18 years old or older than 45 years old;\n* Ovulatory disorders caused by premature ovarian failure, pituitary amenorrhea, hypothalamic amenorrhea, and thyroid dysfunction;\n* Congenital adrenal hyperplasia, reservoir Hin syndrome, hyperprolactinemia, adrenal tumors and other diseases that cause hyperandrogenism;\n* Abnormal liver or renal function((≥ 3 times of the upper limit of normal range)\n* Type 1 diabetes, single gene mutation diabetes, or pancreatic damage Diabetes or other secondary diabetes caused by diabetes;\n* History of malignant tumors;\n* Severe infection, severe anemia, neutropenia and other systemic chronic diseases;\n* Undergo total hysterectomy or ovarian adnexectomy;\n* Mental illness, dementia or other cognitive behavioral problems;\n* Use hypoglycemic drugs that may affect insulin resistance and androgen levels in the last 3 months, including thiazolidinediones, metformin, SGLT-2, and acarbose and GLP-1RA and other drugs;\n* Use letrozole, clomiphene, oral contraceptives, glucocorticoids, gonadotropins, gonadotropin-releasing hormone agonists, anti-androgens (spironolactone, Cyproterone acetate, flutamide, etc.) and other drugs for the treatment of PCOS.","FEMALE","45 Years",{"count":175,"type":22},3000,"The investigators collected clinical data and serum samples of patients with polycystic ovary syndrome (PCOS) in this study, used statistical software such as SPSS for date analysis, and used experimental techniques such as ELISA and flow cytometry to detect serum samples, aiming to explore the relationship between the body anthropometry, skin conditions, psychosomatic status, diet, sleep, exercise, glucose and lipid metabolism, gonadal hormones, and body fat distribution in patients with polycystic ovary syndrome, and to discovery new biomarkers. Multidisciplinary exploration of the mechanisms of disease occurrence and development, the establishment of a PCOS multicenter, multidisciplinary and multidimensional clinical research database, combined with the established statistical analysis strategy for big data and analysis, to promote the realization of more accurate personalized medicine.",[178],"Polycystic Ovary Syndrome",[178,180,181,182],"Clinical characteristics","New biomarkers","Multidisciplinary","2026-03-05",{"date":185,"type":34},"2026-03-09",{"date":187,"type":34},"2023-09-18",{"date":189,"type":22},"2026-07-30",{"name":40,"class":41},{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":42},"100625601","ai-empowered-fundus-platform-100625601","NCT07424755","AI-Empowered Fundus Platform","AI-Empowered Fundus Imaging: Building an Intelligent Platform for Diagnosis, Treatment, and Early Warning of Fundus Diseases","Inclusion Criteria:\n\nPatients with a diagnosis of cataract and high myopia and posterior staphyloma, who underwent comprehensive ophthalmic examinations including ultra-widefield fundus photography (Optos), B-scan ultrasonography, and optical coherence tomography (OCT). Baseline data, including demographics, health status, ophthalmic history, and ocular biometric parameters, were completely documented.\n\nExclusion Criteria:\n\nPatients with poor-quality images affecting PSS identification, severe coexisting ocular diseases including glaucoma, diabetic retinopathy that cause media opacities, or severe systemic diseases that could interfere with the study outcomes.",{"count":199,"type":22},1000,"According to estimates by the World Health Organization, approximately half of the global adult population currently suffers from varying degrees of myopia. In urban areas of China, the myopia rate among primary school students has reached about 40%, and can exceed 80% in high school students. The proportion of patients with high myopia (refractive error greater than 600 degrees) is also increasing year by year. This group is more prone to severe visual problems, including an increased risk of complications such as cataracts, glaucoma, and macular degeneration. Pathological myopia is the main risk factor for vision loss caused by high myopia. In such patients, the elongation of the ocular axis leads to local thinning and protrusion of the posterior pole of the eyeball, forming a posterior scleral staphyloma. Posterior scleral staphyloma is the most representative pathological feature of pathological myopia. Local dilation of the choroid leads to thinning and stretching of the retina, which may ultimately cause problems such as macular retinal schisis, seriously affecting vision and even leading to blindness.\n\nThis project aims to develop a multimodal intelligent screening system by combining the excellent imaging technology and advanced artificial intelligence (AI) of the Optos non-mydriatic ultra-wide-angle laser scanning ophthalmoscope, B-scan ultrasonography ophthalmic diagnostic instrument, and optical coherence tomography (OCT). The system is designed to achieve precise identification and assessment of ocular fundus diseases, especially pathological myopia, and particularly the core condition of posterior scleral staphyloma (PSS). Simultaneously, a vision prediction model will be constructed to assist doctors in formulating personalized diagnosis and treatment strategies, predicting the trend of vision deterioration, and enhancing the effectiveness of early intervention. This system is expected to significantly improve the prevention and control of pathological myopia, reduce the risk of blindness, and play a pivotal role in telemedicine services, benefiting people in remote areas and promoting public health equity and service quality.",[202],"High Myopia","2026-02-14",{"date":205,"type":34},"2026-02-20",{"date":207,"type":34},"2024-10-01",{"date":209,"type":22},"2026-12",{"name":40,"class":41},{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":23,"phases":220,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":229,"leadSponsor":231,"locationsCount":42},"100576284","efficacy-and-safety-of-renal-denervation-on-isolated-diastolic-hypertension-100576284","NCT06783296","Efficacy and Safety of Renal Denervation on Isolated Diastolic Hypertension","Efficacy and Safety of Renal Denervation on Isolated Diastolic Hypertension: A Multicenter, Double-Blind, Randomized, Sham-Controlled Clinical Trial","Inclusion Criteria\n\n1. Age ≥18 years, with no restriction on sex or ethnicity;\n2. Diagnosis of primary hypertension, with no prior use of antihypertensive medication, and in the untreated state presenting with office systolic blood pressure (SBP) \\\u003C140 mmHg and diastolic blood pressure (DBP) ≥90 mmHg, as well as 24-hour ambulatory blood pressure monitoring (ABPM) showing SBP \\\u003C130 mmHg and DBP ≥80 mmHg;\n3. Willingness to participate and provision of written informed consent.\n\nExclusion Criteria\n\n1. DBP ≥110 mmHg;\n2. Secondary hypertension;\n3. Requirement for antihypertensive or blood pressure-lowering medications due to comorbid conditions (e.g., SGLT2 inhibitors, GLP-1 receptor agonists);\n4. Cardiac arrhythmias interfering with blood pressure measurement (e.g., atrial fibrillation);\n5. Contraindications to RDN, including renal transplantation, renal insufficiency (eGFR \\\u003C45 mL\u002Fmin\u002F1.73 m²), renal artery anatomy unsuitable for the procedure (inability to access the renal vasculature; renal artery diameter \\\u003C4 mm or length \\\u003C20 mm; hemodynamically or anatomically significant renal artery abnormalities or stenosis; prior coronary or renal artery interventions including angioplasty or stenting), and severe hepatic impairment;\n6. Contraindications to interventional procedures such as coagulopathy;\n7. Pregnancy, planning pregnancy, or breastfeeding;\n8. Life expectancy \\\u003C1 year;\n9. Participation in another clinical trial.",{"count":219,"type":22},124,[25],"This study aims to evaluate the efficacy and safety of renal denervation (RDN) in patients with isolated diastolic hypertension (IDH). The randomized, double-blind, sham-controlled, multicenter clinical trial will recruit 124 participants (62 in the treatment group and 62 in the sham control group) to assess changes in mean 24-hour ambulatory diastolic blood pressure over a 6-month follow-up period. The study is expected to provide evidence for the use of RDN as a treatment for IDH.",[223,224],"Hypertension","Renal Denervation Therapy","2026-01-28",{"date":227,"type":34},"2026-02-02",{"date":36,"type":22},{"date":230,"type":22},"2028-07-31",{"name":40,"class":41},{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":17,"minAge":239,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":23,"phases":243,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":254,"locationsCount":42},"100618167","efficacy-and-safety-of-coenzyme-i-for-injection-on-vascular-aging-100618167","NCT07328100","Efficacy and Safety of Coenzyme I for Injection on Vascular Aging.","A Randomized, Double-blind, Parallel Controlled Clinical Trial to Evaluate the Efficacy of Coenzyme I for Injection in the Treatment of Vascular Aging（Pilot Stydy）","Inclusion Criteria:\n\n1. Ages 40-70 years;\n2. cf-PWV was abnormally elevated and above the upper limit of its age-and blood-pressure matched reference range;\n3. Systolic Blood Pressure \\\u003C 160 mmHg and ≥ 140 mmHg or Diastolic BP \\\u003C 100 mmHg ≥ 90mmHg;\n4. Signed informed consent.\n\nExclusion Criteria:\n\n1. Consumption of foods or medications containing high levels of NAD+, NR, NAM, NMN, or niacin-related components (including Vitamin B3 and natural health products) within 3 months prior to screening；\n2. History of major cardiovascular or cerebrovascular events, including myocardial infarction, angina, stroke, or hospitalization for arterial revascularization；\n3. Systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg；\n4. Diagnosis of malignant tumor；\n5. Known allergy or history of severe adverse reactions to Coenzyme I injection or any of its components；\n6. History of severe allergies or infusion reactions；\n7. Women who are pregnant, breastfeeding, or planning pregnancy；\n8. Severe hepatic or renal dysfunction: ALT or AST \\> 5 times the upper limit of normal; glomerular filtration rate ≤ 30 mL\u002Fmin\u002F1.73 m²；\n9. Concurrent participation in another clinical trial without completion of the follow-up period；\n10. Other conditions deemed by the investigator as unsuitable for inclusion, such as psychiatric or psychological disorders.","40 Years","70 Years",{"count":242,"type":22},60,[25],"Emerging evidence identifies vascular aging independently predicting cardiovascular events, yet effective clinical interventions remain lacking. Nicotinamide adenine dinucleotide (NAD+) is an essential cofactor whose levels decline with age, and preclinical studies suggest that boosting NAD+ can improve vascular function and structure. Preliminary clinical studies in healthy older adults indicate that supplementation with NAD+ precursors, such as nicotinamide riboside(NR) or nicotinamide mononucleotide (NMN), can reduce arterial stiffness as measured by pulse wave velocity (PWV). However, whether NAD+ supplementation can improve vascular endothelial function and exert anti-stiffening effects in patients who have already developed measurable arterial stiffness remains unknown. Based on this evidence, the investigator hypothesize that the Coenzyme I for Injection will reverse vascular aging in older adults with established arterial stiffening.",[246,247],"Vascular Aging","NAD","2025-12-28",{"date":250,"type":34},"2026-01-08",{"date":252,"type":22},"2026-01-16",{"date":64,"type":22},{"name":40,"class":41},{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":260,"eligibilityCriteria":261,"healthyVolunteers":262,"sex":17,"minAge":18,"maxAge":118,"enrollmentInfo":263,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":265,"conditions":266,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":4},"100608664","a-clinical-study-on-the-safety-tolerance-and-preliminary-efficacy-of--t-cell-injection-in-the-treatment-of-advanced-bladder-cancer-100608664","NCT07204496","A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer","γδ-T-BLADDER","Inclusion Criteria:\n\nThe subject voluntarily participates in this study, signs the informed consent form, demonstrates good compliance, and agrees to follow-up.\n\nAged 18-75 years, regardless of gender.\n\nDiagnosed with primary bladder cancer confirmed by histopathology or clinical diagnostic criteria, clinically assessed as unresectable, and having failed at least two prior lines of standard therapy.\n\nAdequate organ function:\n\n1. Hematologic system (no transfusion or hematopoietic growth factor therapy within 14 days prior to enrollment):\n\n   Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL\n\n   Platelets (PLT) ≥60×10⁹\u002FL\n\n   Hemoglobin (Hb) ≥90 g\u002FL\n2. Liver function:\n\n   Total bilirubin (TBIL) ≤1.5×ULN\n\n   Alanine aminotransferase (ALT) ≤3×ULN\n\n   Aspartate aminotransferase (AST) ≤3×ULN\n\n   Albumin ≥2.8 g\u002FdL\n3. Coagulation function:\n\n   Activated partial thromboplastin time (APTT) ≤1.5×ULN\n\n   International normalized ratio (INR) or prothrombin time (PT) within normal range\n4. Renal function:\n\n   Serum creatinine ≤1.5×ULN, or\n\n   Creatinine clearance (Ccr) ≥50 mL\u002Fmin (calculated using Cockcroft-Gault formula; applies only if creatinine \\>1.5×ULN)\n5. Thyroid function:\n\n   Thyroid-stimulating hormone (TSH) ≤1×ULN\n\n   Free triiodothyronine (FT3) ≤1×ULN\n\n   Free thyroxine (FT4) ≤1×ULN\n6. Cardiovascular function:\n\nLeft ventricular ejection fraction (LVEF) ≥50% by echocardiography\n\nAJCC Bladder Cancer Stage III or IV.\n\nEastern Cooperative Oncology Group (ECOG) performance status score of 0-1.\n\nAt least one measurable lesion (according to mRECIST criteria).\n\nExpected survival time ≥6 months.\n\nMale subjects with partners of childbearing potential must use reliable and effective contraception from signing the informed consent form until 180 days after the last dose of the study drug. Male subjects with pregnant partners must use condoms and require no additional contraception methods.\n\nExclusion Criteria:\n\nPrior treatments within 28 days before the first dose:\n\n1. Chemotherapy, radiotherapy, biologic therapy, immunotherapy, targeted therapy, local therapy, or traditional Chinese medicine with明确抗肿瘤适应症 (clear antitumor indications).\n2. Major surgical procedures or failure to recover from side effects of such surgeries (excluding minor procedures, e.g., appendectomy, tumor biopsy).\n3. Participation in other interventional drug clinical trials (excluding observational studies or survival follow-up).\n\nFailure to recover from prior antitumor therapy-related toxicities (except alopecia) (i.e., toxicity still \\> Grade 1 or not returned to baseline).\n\nConcurrent or history of other malignancies, except:\n\nCurative basal cell or squamous cell skin cancer\n\nCarcinoma in situ of the cervix\n\nPapillary thyroid carcinoma\n\nDuctal carcinoma in situ of the breast\n\nOther malignancies with disease-free survival \\>5 years\n\nUncontrolled diabetes despite optimal supportive care.\n\nPresence of gastrointestinal bleeding, refractory ascites, hepatic encephalopathy, or hepatorenal syndrome.\n\nHistory or presence of autoimmune diseases (e.g., rheumatoid arthritis).\n\nNeurological diseases, diffuse leptomeningeal disease, or comorbid neurodegenerative disorders.\n\nHistory or planned stem cell or organ transplantation during the study.\n\nAny of the following within 6 months before the first dose:\n\n1. Cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism, or other clinically significant thromboembolic events.\n2. Unstable angina, myocardial infarction, or symptomatic chronic heart failure.\n3. Ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes).\n4. Coronary\u002Fperipheral artery bypass grafting.\n5. Current or history of congestive heart failure (NYHA Class II-IV).\n6. Uncontrolled hypertension despite medication (systolic BP ≥160 mmHg and\u002For diastolic BP ≥100 mmHg).\n\nActive infections, including:\n\n1. Clinically uncontrolled active infections within 7 days before the first dose (e.g., acute pneumonia, unexplained persistent fever).\n2. Hepatitis B (HBsAg-positive and HBV-DNA \\>1000 IU\u002FmL; HBV carriers must receive antiviral therapy per local guidelines and commit to ongoing treatment during the study).\n3. Hepatitis C (HCV antibody-positive).\n4. HIV or Treponema pallidum (TP) infection.\n\nRequirement for systemic corticosteroids (\\>10 mg\u002Fday prednisone or equivalent) or other immunosuppressants.\n\nPregnancy or lactation.\n\nAny uncontrolled concurrent condition (including psychiatric disorders or substance abuse) deemed by the investigator to compromise subject cooperation or trial participation, or any other reason making the subject unsuitable for the study.",true,{"count":264,"type":22},20,"We plan to enroll 20-29 patients with advanced bladder cancer to undergo T-cell therapy. Each treatment cycle consists of three T-cell infusions, with two cycles planned per patient. Each cycle will include imaging studies, laboratory tests, and vital sign monitoring to evaluate quality of life and treatment efficacy. Through real-world clinical data, we aim to scientifically determine whether this novel T-cell therapy can significantly alter the pathological progression of tumors and improve patient outcomes. Ultimately, we seek to benefit a broader patient population by achieving long-term tumor-bearing or tumor-free survival, transforming cancer management into a chronic disease model and improving patients' quality of life.",[267],"Advanced Bladder Cancer","2025-09-24",{"date":270,"type":34},"2025-10-02",{"date":272,"type":22},"2025-09-26",{"date":274,"type":22},"2026-12-31",{"name":40,"class":41},{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":283,"targetDuration":285,"studyType":97,"phases":4,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":4},"100599120","isavuconazole-in-critically-ill-patients-efficacy-and-safety-100599120","NCT07080359","Isavuconazole in Critically Ill Patients: Efficacy and Safety","Isavuconazole in Critically Ill Patients: A Study on Antifungal Efficacy and Safety","Inclusion Criteria:\n\n* Adult critically ill patients (≥18 years) admitted to ICU with suspected or confirmed invasive fungal infection (IFI)\n* IFI diagnosis per EORTC\u002FMSGERC 2019 criteria\n\nExclusion Criteria:\n\n* Drug allergy\n* Inherited short QT syndrome\n* Contraindications for nasogastric\u002Foral drug delivery\n* \\\u003C18 years old",{"count":284,"type":22},75,"3 Months","Due to factors such as disease status, gastrointestinal conditions, commonly used medications (e.g., vasopressors), and cardiac output, the plasma concentration of isavuconazole in critically ill patients may differ from that in healthy individuals, exhibiting significant variability.\n\nThis study aims to explore the variability of isavuconazole plasma concentrations in critically ill patients and its correlation with efficacy and adverse effects. The research includes:\n\n1. The distribution and variability of isavuconazole plasma concentrations in critically ill patients;\n2. Clinical outcomes;\n3. Adverse effects.",[288,289,290],"Fungal Infection","Aspergillosis","Mucormycosis","2025-07-14",{"date":293,"type":34},"2025-07-23",{"date":295,"type":22},"2025-08-01",{"date":297,"type":22},"2030-12-31",{"name":40,"class":41},{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":17,"minAge":239,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":316,"leadSponsor":318,"locationsCount":4},"100594668","research-based-on-iolmaster700-cataract-diagnosis-and-classification-system-100594668","NCT07022444","Research Based on IOLMaster700 Cataract Diagnosis and Classification System","Research on Heterogeneous Intelligent Algorithm Based on IOLMaster700 Cataract Diagnosis and Classification System","Inclusion Criteria:\n\n* A. Age between 18 and 90 years B. Diagnosed with age-related and\u002For complicated cataract (diagnosed according to LOCS III classification) C. The patient has signed an informed consent form\n\nExclusion Criteria:\n\n* A. Exclude patients with corneal diseases, uveitis, vitreoretinal diseases, or refractive media opacities caused by conditions such as retinal detachment with silicone oil tamponade B. History of previous ophthalmic disease treatment or surgery C. Poor-quality or missing imaging data D. Pupil diameter \\\u003C 2.5 mm or loss of fixation during examination, resulting in inability to obtain sufficient lens data",{"count":307,"type":22},2000,"Cataract is a major cause of blindness due to eye diseases. Methods for evaluating the degree of lens opacification in cataracts are divided into subjective and objective methods. The commonly used subjective method is the Lens Opacification Classification System (LOCS Ⅲ), while the objective methods mainly include the Dysfunctional Lens Index (DLI) of the Ray Tracing aberration analysis system, the PNS score of the Pentacam anterior segment analysis system, etc. Subjective diagnosis may lead to certain misjudgments, which have affected clinical diagnosis and treatment. There is an urgent need to add objective diagnostic measures to assist clinical work. The Scanning Source Optical Coherence Tomography (SS - OCT) biometer - IOL Master 700 forms an OCT imaging of the eye based on the swept - source optical coherence tomography (OCT) biometric technology. It can visually show the longitudinal section of the entire lens, and the clear display of the patient's lens tomographic OCT image is obtained through image visualization measurement.\n\nThe main purpose of this study is to analyze the lens images obtained by the IOLmaster 700. Based on the current mainstream algorithm models such as ResNet - 34 and XGBoost, develop a heterogeneous accelerated artificial intelligence algorithm according to our research needs to accurately calculate the degree of lens opacification. And write image analysis software by ourselves to automatically calculate the required indicators and output them. Establish a heterogeneous accelerated artificial intelligence - assisted lens opacification grading and prediction system, supporting software for biometer equipment, and a cataract lens image database. The software provides online service functions, and all researchers can use the image analysis function of the software after logging in, truly realizing the sharing of large instrument supporting software operations. Thereby improving the accuracy and efficiency of clinical diagnosis and treatment, the prognostic prediction level of patients after cataract surgery, guiding clinical diagnosis and treatment more accurately, and at the same time, it can be used as a tool for community screening.",[310,311],"Cataract","Artificial Intelligence (AI)","2025-06-08",{"date":314,"type":34},"2025-06-15",{"date":314,"type":22},{"date":317,"type":22},"2025-12-31",{"name":40,"class":41},{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":23,"phases":328,"briefSummary":329,"conditions":330,"keywords":333,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":342},"100593707","dcb-for-cad-with-type-2-diabetes-100593707","NCT07009938","DCB for CAD With Type 2 Diabetes","Long-Term Efficacy and Safety of Drug-Coated Balloon Angioplasty in Patients With Coronary Artery Disease and Type 2 Diabetes: A Multicenter, Prospective, Randomized Controlled Trial","DCBinT2DM","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosed CAD with ≥70% stenosis in ≥1 coronary artery confirmed by coronary angiography\n* Diagnosed type 2 diabetes (per WHO criteria)\n* Target lesion suitable for DCB (diameter 2.0-4.0 mm, length ≤40 mm)\n* Informed consent provided\n\nExclusion Criteria:\n\n* Prior coronary artery bypass surgery or PCI with complications\n* STEMI within 24 hours\n* Severe hepatic\u002Frenal dysfunction\n* Active bleeding or uncontrolled anticoagulation\n* Allergy to DCB components\n* Pregnancy or lactation\n* Psychiatric conditions limiting compliance",{"count":199,"type":22},[25],"Patients with coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) often present with diffuse, complex lesions and a higher risk of in-stent restenosis after PCI. While drug-eluting stents (DES) remain the standard treatment, their long-term efficacy in diabetic patients is suboptimal. Drug-coated balloons (DCBs) offer a \"leave nothing behind\" strategy by delivering anti-proliferative drugs without permanent implants, potentially reducing restenosis and adverse events. Although DCBs have shown promise in selected lesion types, evidence in T2DM patients is limited, particularly from prospective, randomized trials. This study aims to evaluate the efficacy and safety of DCB angioplasty compared to conventional strategies in patients with CAD and T2DM, focusing on angiographic outcomes, symptom relief, and major adverse cardiovascular events.",[331,332],"Coronary Artery Disease","Diabete Type 2",[334],"coronary artery disease; type 2 diabetes mellitus; drug-coated balloon; target lesion revascularization; major adverse cardiac events","2025-06-06",{"date":312,"type":34},{"date":338,"type":22},"2025-07-01",{"date":340,"type":22},"2028-07-01",{"name":40,"class":41},6,{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":17,"minAge":350,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":23,"phases":353,"briefSummary":354,"conditions":355,"keywords":357,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":42},"100553647","treatment-of-perioperative-neurocognitive-disorders-with-olfactory-enrichment-100553647","NCT06488807","Treatment of Perioperative Neurocognitive Disorders With Olfactory Enrichment","Treatment of Perioperative Neurocognitive Disorders With Olfactory Enrichment: Study Protocol for a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥65 years old.\n2. Having a scheduled surgery (≥2 hours, general anesthesia) (e.g., total hip replacement, toal knee replacement, open reduction and internal fixation of hip and lumbar spine).\n3. Being able to complete neuropsychological tests, 3D-CAM and CAM-S.\n4. Chinese Mandarin as their native language.\n5. Edmonton frailty scale (EFS) score ≥ 6.\n\nExclusion Criteria:\n\n1. Having delirium, assessed by 3D-CAM, before surgery.\n2. Having a brain tumour, stroke or mental disorders (eg, major depressive disorder or dementia).\n3. Participating in other clinical studies at the time of screening.\n4. Unwillingness to comply with the protocol or procedures.","65 Years",{"count":352,"type":22},686,[25],"Perioperative neurocognitive disorder (PND) is one of the most common postoperative complications among elderly patients. However, the mechanism and targeted intervention of PND remains unclear. Our previous clinical studies demonstrated the association between olfactory impairment and PND. Moreover, our translational studies showed that anesthesia\u002Fsurgery induced olfactory impairment and caused cognitive impairment in mice and olfactory enrichment could prevent the anesthesia\u002Fsurgery-induced cognitive impairment. However, there was no clinical investigation to determine whether olfactory enrichment can mitigate PND in elderly patients. Therefore, we propose determining whether olfactory enrichment can prevent and\u002For treat PND in elderly patients.",[356],"Perioperative Neurocognitive Disorder",[356,358],"Odor Enrichment","2025-05-13",{"date":361,"type":34},"2025-05-14",{"date":363,"type":34},"2025-04-07",{"date":365,"type":22},"2028-12-31",{"name":40,"class":41},{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":350,"enrollmentInfo":374,"targetDuration":4,"studyType":23,"phases":376,"briefSummary":377,"conditions":378,"keywords":379,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":386,"leadSponsor":387,"locationsCount":42},"100589045","intervention-study-on-digital-health-management-100589045","NCT06949306","Intervention Study on Digital Health Management","Intervention of a Digital Health Management Program in Patients With Cardiometabolic Disorders: a Real-world Study","Inclusion Criteria:1. Age 18-65 years old; 2. Meet one of the following three conditions:\n\n1. Diastolic hypertension (systolic blood pressure \\\u003C 140 MMHG and diastolic blood pressure ≥90mmHg)\n2. Glycosylated hemoglobin (6.0-6.5)\n3. Obesity (BMI≥28kg\u002Fm²)\n4. Mild hyperlipemia: total cholesterol (TC) ≥5.2 mmol\u002FL and \\\u003C 6.2 mmol\u002FL, or low-density lipoprotein cholesterol (LDL-C) ≥3.4 mmol\u002FL and \\\u003C 4.1 mmol\u002FL 3. Antihypertensive or lipid-lowering medications have not been started 4. Use a smartphone and volunteer\n\nExclusion Criteria:\n\n1. Complicated with chronic liver and kidney disease, coronary heart disease, heart failure and severe valvular disease\n2. Previous cardiovascular and cerebrovascular events\n3. Diastolic blood pressure ≥99mmHg\n4. Glycated hemoglobin ≥6.5\n5. Other life expectancy such as cancer is less than 5 years\n6. Participate in other clinical trials",{"count":375,"type":22},300,[25],"The aim of this study is to construct a digital precision intervention system for cardiometabolism disorders based on the characteristics of the Chinese population, focusing on the core components of metabolic syndrome such as hypertension, hyperglycemia, and obesity. Through dynamic monitoring of wearable devices, the individualized risk factors (including genetic predisposition, lifestyle, and psychological factors) of metabolic disorders were systematically analyzed, and dynamic intervention strategies were formulated accordingly. The closed-loop management of \"monitor-feedback-optimization\" based on the digital platform will provide patients with one-stop metabolic risk assessment and panoramic health management plan, realizing a paradigm shift from \"generalized intervention\" to \"precise regulation\". By reducing the abnormal fluctuations of key metabolic indicators such as blood pressure, blood glucose, and blood lipids, the risk of cardiovascular events will eventually be reduced, the long-term quality of life of patients will be improved, and a practical path of \"digital therapy\" can be promoted for the prevention and control of chronic diseases in China",[223,29],[380,381],"Cardiometabolic abnormalities","Digital Interventions","2025-04-21",{"date":384,"type":34},"2025-04-29",{"date":338,"type":22},{"date":297,"type":22},{"name":40,"class":41},{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":350,"enrollmentInfo":395,"targetDuration":4,"studyType":23,"phases":396,"briefSummary":397,"conditions":398,"keywords":399,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":408,"locationsCount":409},"100588479","etiological-classification-guided-individual-intervention-in-primary-hypertension-100588479","NCT06941935","Etiological Classification-guided Individual Intervention in Primary Hypertension","Etiological Classification-guided Individual Intervention in Primary Hypertension: An All-comer Registry Study","Inclusion Criteria:\n\n* Age 18-65 years.\n* Diagnosed primary hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg).\n* signed informed consent.\n\nExclusion Criteria:\n\n* Secondary hypertension or arrhythmias affecting blood pressure accuracy (e.g., atrial fibrillation).\n* Comorbidities such as diabetes, chronic kidney disease (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²), coronary artery disease, heart failure, or serious valvular heart disease.\n* History of stroke or myocardial infarction.\n* Pregnancy, breastfeeding, or planning to become pregnant.\n* Life expectancy \\\u003C 1 year.\n* Participation in another clinical trial.",{"count":307,"type":22},[25],"Eligible participants will first undergo a 1-week home blood pressure diary and 24-hour ambulatory blood pressure assessment. After a confirmed diagnosis of hypertension, etiological subtyping will be performed. Based on the blood pressure evaluation results and etiological classification, the most appropriate antihypertensive medication will be selected. Simultaneously, a personalized lifestyle prescription will be provided according to the patient's individual circumstances. Following medication initiation, participants will continue to monitor their blood pressure through home diaries. Monthly evaluations will be conducted, and if blood pressure fails to reach the target value, medication adjustments will be made based on the blood pressure diary until target levels are achieved. This regimen will be maintained long-term.",[223],[400,401],"Etiological Classification","Digital Intervention","2025-04-16",{"date":404,"type":34},"2025-04-24",{"date":406,"type":22},"2025-06-01",{"date":297,"type":22},{"name":40,"class":41},2,{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":17,"minAge":417,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":23,"phases":420,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":431,"locationsCount":42},"100573350","myocardial-infarction-and-periodontitis-periodontal-health-intervention-100573350","NCT06745141","Myocardial Infarction and Periodontitis: Periodontal Health Intervention.","Oral Health Intervention Study in Patients with Myocardial Infarction and Periodontal Disease: a Simulated RCT Trial","Inclusion Criteria:\n\n* 1)Patients diagnosed with ST-segment elevation myocardial infarction (STEMI). 2)Patients with severe periodontal disease, defined as:\n\n  * 5 teeth with clinical attachment loss (CAL) ≥ 4 mm.\n\n    * Subgingival probing depth (PD) ≥ 6 mm. ③≥ 8 teeth with gingival bleeding on probing (BOP). 3）Age ≥30 years. 4）Written informed consent provided.\n\nExclusion Criteria:\n\n* 1\\) under 30 years old; 2) HIV positive, chronic inflammation, tumor disease, drug dependence, use of anticonvulsants, use of immunosuppressive agents, pregnancy, and lactation; 3) significant tooth loss (number of remaining teeth \\\u003C 8); 4) long hospital stay (\\>10 days), new myocardial infarction before randomization, and stent thrombosis; 5) Refusal to sign informed consent.","30 Years",{"count":419,"type":22},100,[25],"The aim of this study is to establish a shared database of acute myocardial infarction patients with periodontitis, to clarify the clinical benefits of periodontitis intervention on acute myocardial infarction patients through simulated RCT study, and to establish a high-level database of acute myocardial infarction patients with periodontitis, so as to promote the application of oral health intervention in clinical practice.",[423,424],"Acute Myocardial Infarction (AMI)","Periodontal Disease","2024-12-17",{"date":427,"type":34},"2024-12-20",{"date":429,"type":34},"2020-12-01",{"date":317,"type":22},{"name":40,"class":41},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":439,"enrollmentInfo":440,"targetDuration":4,"studyType":23,"phases":441,"briefSummary":442,"conditions":443,"keywords":446,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":42},"100568459","a-new-cardiac-rehabilitation-treatment-in-the-application-of-ischemic-heart-disease-100568459","NCT06681506","A New Cardiac Rehabilitation Treatment in the Application of Ischemic Heart Disease","A New Cardiac Rehabilitation Treatment in the Application of Ischemic Heart Disease: a Prospective, Randomized Controlled Clinical Study","Inclusion Criteria:\n\n* Aged between 18 and 85 years old\n* Female subjects no pregnancy\n* The main admission diagnosis of ischemic heart disease (coronary heart disease, myocardial infarction, ischemic heart failure, etc.)\n* The need for cardiac rehabilitation treatment\n\nExclusion Criteria:\n\n* acute respiratory distress syndrome (ARDS);\n* acute episode of COPD;\n* uncontrolled pulmonary infection;\n* acute heart failure; acute pulmonary embolism;\n* acute myocarditis\u002Fpericarditis;\n* severe arrhythmia (degree II or III atrioventricular block, atrial flutter, or atrial fibrillation);\n* sternotomy, rib fracture, thoracic deformity, or other neurological diseases that may affect respiratory muscles","85 Years",{"count":419,"type":22},[25],"Cardiac rehabilitation is an important link in cardiovascular disease. This study mainly explores the effectiveness of new cardiac rehabilitation therapy (early respiratory rehabilitation, phase I rehabilitation, exercise therapy, external counterpulsation, extracorporeal shock wave, etc.) on patients with ischemic heart disease such as coronary heart disease and heart failure, and the compliance of home rehabilitation compared with traditional cardiac rehabilitation therapy (traditional exercise rehabilitation, rehabilitation education, etc.).",[444,445],"Ischemic Heart Disease","Cardiac Rehabilitation",[447,448,449,450,444],"coronary atherosclerotic cardiopathy","Cardiac Shock Wave Therapy","exercise rehabilitation","cardiac rehabilitation","2024-11-07",{"date":453,"type":34},"2024-11-08",{"date":455,"type":34},"2024-01-01",{"date":457,"type":22},"2031-12-31",{"name":40,"class":41},{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":465,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":23,"phases":468,"briefSummary":469,"conditions":470,"keywords":472,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":342},"100567659","noninvasive-assessment-of-pulmonary-fluid-levels-by-remote-dielectric-sensing-technology-to-improve-cardiac-insufficieney-during-ischemia-reperfusion-and-clinical-outcomes-in-myocardial-infarction-100567659","NCT06671067","Noninvasive Assessment of Pulmonary Fluid Levels by Remote Dielectric Sensing Technology to Improve Cardiac InsUfficieney During Ischemia-Reperfusion and Clinical Outcomes in MyocArdiaL Infarction","Noninvasive Assessment of Pulmonary Fluid Levels by Remote Dielectric Sensing (ReDS™) Technology to Improve Cardiac Insufficiency During Ischemia-reperfusion and Clinical Outcomes in Myocardial Infarction","NATURAL","Inclusion Criteria:\n\n1. Patients were required to be aged ≥ 18 years and to be hospitalized for a primary diagnosis of AMI,\n2. AMI patients accompanied by cardiac insufficiency following coronary revascularization, which is characterized by the symptoms and signs of fluid overload, regardless of left ventricular ejection fraction (LVEF), and have an N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration of ≥ 400 pg\u002FL or a BNP concentration of ≥ 100 pg\u002FL.\n\nExclusion Criteria:\n\n1. Patient's physical characteristics that prevented the use of the ReDS system (height of \\\u003C155 or \\>190 cm; body mass index of \\\u003C22 or \\>39 kg\u002Fm2)\n2. Patients with chronic obstructive pulmonary disease or other lung diseases that might confound ReDS values\n3. Patients with a left ventricular assist device or undergoing cardiac transplantation;\n4. Patients with congenital heart malformations or intrathoracic mass that would affect right lung anatomy;\n5. Patients with end-stage renal disease on hemodialysis;\n6. Patients whose life expectancy less than 12 months due to noncardiac comorbidities\n7. Patients who participate in another randomized studies.",{"count":307,"type":22},[25],"To explore whether a ReDS-guided strategy for AMI patients with cardiac insufficiency following coronary flow reperfusion is superior to routine care for improving outcomes.",[150,471],"Acute Decompensated Heart Failure (ADHF)",[473,474,475,476],"Remote dielectric sensing system","Acute myocardial infarction","Acute heart failure","Clinical outcomes","2024-10-31",{"date":479,"type":34},"2024-11-04",{"date":481,"type":22},"2024-11-01",{"date":483,"type":22},"2027-06",{"name":40,"class":41},{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":4,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":172,"minAge":18,"maxAge":173,"enrollmentInfo":492,"targetDuration":4,"studyType":23,"phases":493,"briefSummary":494,"conditions":495,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":42},"100541138","pcos-immune-function-predicts-metformin-efficacy-100541138","NCT06325956","PCOS Immune Function Predicts Metformin Efficacy","Prediction of Immune Status on the Efficacy of Metformin in the Treatment of Polycystic Ovary Syndrome","Inclusion Criteria:\n\n* aged 18-45 years\n* Diagnosis of PCOS with the Rotterdam diagnosis criteria (2003)\n\nExclusion Criteria:\n\n* Pregnant women;\n* Hyperthyroidism or hypothyroidism\n* Severe liver and kidney function injury\n* Cancer patients;\n* Associated with severe infection, severe anemia, neutropenia and other blood system diseases;\n* Have type 1 diabetes, single-gene mutated diabetes or other secondary diabetes;\n* Patients with mental illness or intellectual disability;\n* Have taken drugs for PCOS treatment in the last three months;\n* Have a long history of taking hormone therapy;\n* Currently or recently participating in another clinical trial.",{"count":419,"type":22},[25],"In this study, the investigators will include PCOS patients who meet the trial criteria, introduce participants to the content of this study, and invite participants to participate. The immune function of peripheral blood samples of PCOS patients was detected by flow cytometry. Participants were further treated with metformin for 6 months and followed up after the intervention. The objective of this study was to investigate immune markers related to the efficacy of metformin in PCOS patients and to predict the efficacy of metformin in PCOS patients using immune function.",[178,496,497],"Metformin","Immune Function","2024-03-21",{"date":500,"type":34},"2024-03-22",{"date":502,"type":34},"2024-03-16",{"date":504,"type":22},"2026-07-01",{"name":40,"class":41},{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":17,"minAge":19,"maxAge":513,"enrollmentInfo":514,"targetDuration":4,"studyType":23,"phases":516,"briefSummary":518,"conditions":519,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":4},"100505017","phase-4-clinical-study-of-gkt-in-diabetes-related-dementia-100505017","NCT05855863","Clinical Study of GKT in Diabetes Related Dementia","Clinical Study of Ginkgo Biloba Ketone Ester Tablets in Diabetes Related Dementia","Inclusion Criteria:\n\n1. Type 2 diabetes with mild cognitive impairment patients aged 65 years or above;\n2. Able to cooperate in completing cognitive function testing;\n3. Patients who can swallow pills\n4. No previous history of stroke，cerebral thrombosis, etc\n\nExclusion Criteria:\n\n1. Type 1 diabetes;\n2. Acute cerebral infarction and myocardial infarction within 3 months;\n3. Severe liver and kidney dysfunction;\n4. Late stage malignant tumors;\n5. Thyroid dysfunction；\n6. Brain injury and cerebral hemorrhage within 3 months；\n7. Folic acid and\u002For vitamin B12 deficiency\n8. Patients who are currently using thrombin inhibitors, defibrillators (with unclear efficacy in ischemic stroke and increased risk of bleeding), antiplatelet drugs, blood activating and stasis resolving agents, and other ginkgo biloba leaf preparations (as they may affect the evaluation of the therapeutic effect of ginkgo biloba ester tablets in this trial), as well as other trial medications.","90 Years",{"count":515,"type":22},370,[517],"PHASE4","Recently a new clinical dementia subgroup based on brain imaging, called \"diabetes related dementia (DrD)\". DrD, unlike Alzheimer's disease and vascular dementia, is considered a \"controllable\" or \"modifiable\" form of dementia. However, there is currently a lack of corresponding treatment measures. Ginkgo biloba ketone ester tablets are extracts of Ginkgo biloba leaves. Previous studies have shown that they can increase cerebral blood flow, reduce cerebrovascular resistance, improve cerebral circulation, and are beneficial for the treatment of cognitive impairment. This project intends to explore the role of ginkgo ketoester tablets in diabetes related dementia through a multicenter randomized double-blind controlled clinical study.",[520],"Dementia","2023-11-09",{"date":523,"type":34},"2023-11-13",{"date":525,"type":22},"2023-12-01",{"date":527,"type":22},"2026-06-30",{"name":40,"class":41},{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":536,"targetDuration":537,"studyType":97,"phases":4,"briefSummary":538,"conditions":539,"keywords":542,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":42},"100447425","the-impact-of-atrial-pressure-change-before-and-after-combined-procedure-100447425","NCT05106270","The Impact of Atrial Pressure Change Before and After Combined Procedure","The Impact of Atrial Pressure Change Before and After One-stop Procedure Combining Catheter Ablation and Left Atrial Appendage Closure on the Prognosis of Patients With Atrial Fibrillation","Inclusion Criteria:\n\n* Atrial fibrillation recorded by 12-lead ECG or Holter that last for longer than 30 seconds within the preceding 6 months;\n* Eligible for left atrial appendage closure, that meet at least one of the followings:\n\n  1. At high risk of stroke (CHA2DS2-VASc score≥3 in female, ≥2 in male) and\u002For bleeding (HAS-BLED score≥3);\n  2. Contraindicated to oral anticoagulation (OAC);\n  3. Refused OAC treatment albeit comprehensively informed of the necessity and benefits of OAC treatment.\n* Capable of understanding and signing the informed consent form.\n* Aged over 18 years.\n\nExclusion Criteria:\n\n* Reversible causes of atrial fibrillation, including thyroid disorders, recent major surgery, trauma, acute alcoholic intoxication;\n* Concomitant arrhythmia including atrial flutter, ventricular tachycardia;\n* A previous history of atrial fibrillation surgery (MAZE surgery) or catheter ablation;\n* A previous history of cardiac surgery including any valvular replacement, septal repair;\n* A recent history of major cardiovascular disease within 3 months, including acute myocardial infarction, ventricular fibrillation;\n* A history of congenital heart disease;\n* A previous history of atrioventricular node ablation;\n* A history of lobectomy due to any medical condition;\n* Complicated by other diseases with life expectation \\\u003C1 year;\n* Women with childbearing potential;\n* Participated in other interventional clinical trials that might affect prognosis;\n* Unable to understand or give informed consent form.",{"count":419,"type":22},"5 Years","One-stop procedure combining catheter ablation (CA) and left atrial appendage closure (LAAC) has been a feasible treatment for patients with atrial fibrillation at high risk of stroke and\u002For bleeding. Although it could achieve considerable rhythm control and stroke prophylaxis, a number of patients has experienced progressive heart failure after the procedure. Notably, previous studies indicate that both pulmonary vein isolation by CA and LAAC could significantly increase left atrial pressure, while currently no study has investigated left atrial pressure change in patients underwent combined procedure. The investigators hypothesise that combined procedure would significantly increase left atrial pressure and subsequently deteriorate cardiac function. Therefore, the investigators aim to measure the left and right atrial pressure change before and after CA and LAAC in combined procedure, and investigate the influence of the pressure change on clinical outcomes.",[540,541],"Atrial Fibrillation","Heart Failure",[543,544,545,546,547],"Left atrial pressure","combined procedure","Catheter ablation","Left atrial appendage closure","Cardiac function","2022-08-30",{"date":550,"type":34},"2022-09-02",{"date":552,"type":34},"2021-11-10",{"date":554,"type":22},"2027-11-10",{"name":40,"class":41},{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":97,"phases":4,"briefSummary":565,"conditions":566,"keywords":571,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":42},"100472747","assessment-and-digital-health-based-intervention-on-subclinical-organ-damage-and-cardiovascular-risk-in-chinese-100472747","NCT05435898","Assessment and Digital-health Based Intervention on Subclinical Organ Damage and Cardiovascular Risk in Chinese","Comprehensive Assessment and Digital-health Based Intervention on Early-stage Cardiovascular Organ Damage and Cardiovascular Risk in Chinese: An All-comer Registry Study","Inclusion Criteria:\n\n* aged 18 years or older\n* willing to participate the study and sign informed consent\n* available for long-term follow-up\n\nExclusion Criteria:\n\n* severe heart disease (NYHA IV)\n* stage 4 or 5 CKD\n* malignant tumors or with life expectancy less than 5 years\n* stroke within 3 months\n* refuse to participate the study or not available for long-term follow up",{"count":564,"type":22},4000,"To comprehensively evaluate subclinical organ damage of Chinese adults and its association with future cardiovascular disease and events.\n\nTo observe the significance of intervention based on digital health in preventing the onset and\u002For progression of subclinical organ damage and cardiovascular disease and events.",[567,568,569,570],"Cardiovascular Diseases","Cardiovascular Morbidity","Subclinical Organ Damage","Digital Health",[572,573,574,575,576,577],"Coronary Heart Disease","Arterial stiffness","Left ventricular hypertrophy","Left ventricular diastolic dysfunction","Intima-media thickness","Cardiovascular events","2022-06-23",{"date":580,"type":34},"2022-06-28",{"date":582,"type":22},"2022-10-01",{"date":584,"type":22},"2029-09-30",{"name":40,"class":41},{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":592,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":594,"enrollmentInfo":595,"targetDuration":537,"studyType":97,"phases":4,"briefSummary":597,"conditions":598,"keywords":599,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":42},"100463164","study-of-the-closed-loop-treatment-concept-of-atrial-fibrillation-in-the-atrial-fibrillation-population-100463164","NCT05311137","Study of the Closed-loop Treatment Concept of Atrial Fibrillation in the Atrial Fibrillation Population","Application of the Closed-loop Treatment Concept of Atrial Fibrillation in the Atrial Fibrillation Population in the Northern Shanghai Community","CONTROL-AF","Inclusion Criteria:\n\n* atrial fibrillation patients；Ability to act autonomously, understand and sign informed consent；\n\nExclusion Criteria:\n\n* none（All patients with atrial fibrillation were enrolled in this study indiscriminately and followed up）","100 Years",{"count":596,"type":22},5000,"This study aims to evaluate the concept of closed-loop treatment of atrial fibrillation for the optimization of the treatment strategy.",[540],[600],"atrial fibrillation；closed-loop treatment；","2022-05-20",{"date":603,"type":34},"2022-05-24",{"date":605,"type":34},"2022-05-01",{"date":607,"type":22},"2032-01-01",{"name":40,"class":41},""]